The launch has already begun, in the United Kingdom. The picture for a generic form of Temodar® in the US is less clear -- as a "pay-to-delay" deal was inked last month (and is likely now undergoing US FTC/DoJ review). Additionally, the federal appeal process (Judge Sue L. Robinson held Merck's patent unenforceable a few months back -- in part, for "inequitable conduct") will take a little time, here in the US, but soon -- very soon -- it will be here, too:
. . . .[Teva is pleased] to announce the launch of temozolomide available in 5mg, 20mg, 100mg, 140mg, 180mg and 250mg strength capsules. Temozolomide is indicated for the oncological treatment of brain tumours. . . .
Robyn Hughes, Director of Primary and Secondary Care at Teva UK Limited said "We are proud to be the first to bring temozolomide to the generic market, and we view this product as an important addition to our oncology portfolio. . . ."
Saving money -- in fact translates to saving more lives -- in this case. Let us hope that the FTC and DoJ do their work, and do it swiftly.
नमस्ते
No comments:
Post a Comment